soul trial oral semaglutide cardiovascular outcomes nejm 2024 2025 Presented at ACC.25: Among participants with type 2 diabetes and disease, chronic kidney disease, or both, (14 mg) was associated with a lower risk of cardiovascular events than placebo Oral Semaglutide and Cardiovascular Outcomes

Skovbjerg et al., 2024)

This means orforglipron can be taken in pill form to achieve similar effects, including weight loss and other improvements in metabolic health, like better blood sugar control, lower blood pressure, and reduced cholesterol

Retatrutide is still investigational and being studied in clinical trials

The drugs may also affect the body long-term, altering hormone levels and resetting the brains appetite control mechanisms

Mistake 4: Injecting into muscle If the needle enters muscle tissue instead of subcutaneous fat, the medication absorbs differently and the injection hurts significantly more